Metabolic Health
4 Metabolic Health Startups Linking Prevention, Monitoring and Treatment
DealBio tracks early-stage metabolic health startups across Europe and North America. These 4 show how the category is stretching from repeated prevention and monitoring into biological intervention and targeted treatment.
- Preventive Health
- Biomarkers
- Microbiome
- Therapeutics
Metabolic health is a continuum rather than a single market. Risk can build over years through changes in weight, glucose regulation, liver function and inflammation, which creates opportunities for products that act before, during and after disease becomes clinically visible.
Across these startups, the common opportunity is to make metabolic risk more actionable by connecting measurement, behavior and biology to a specific intervention. Repeated testing, gut-directed products, workplace prevention and targeted liver therapy all point toward earlier action and more continuous metabolic care.
At a Glance
- Mito HealthUnited States2023Repeated biomarker testing and guidance
- 1stBiomeDenmark2026Engineered probiotics for metabolic health
- Heureka TherapeuticsDenmark2026Liver-targeted metabolic therapeutics
- GoEcoFitGermany2023Employer-funded preventive health
Offering at-cost biomarker testing with AI-guided preventive health insights.
- Country
United States- Founded
- 2023
- Sector
- Consumer health
- Funding stage
- Seed or earlier
- Founders
Why Mito Health stands out
Mito Health combines consumer distribution with a measurable testing workflow. By July 2026, the startup had completed more than one million laboratory tests and availability across all 50 US states, while total disclosed funding had reached $4 million.
The founders also bring relevant consumer and product experience. Kenneth Lou previously grew Seedly past one million monthly users before its sale to ShopBack, while Joel Kek was a technology lead on Singapore's TraceTogether system.
What Mito Health is building
Mito Health gives members access to laboratory biomarker testing at cost, then organizes results into a preventive-health dashboard with AI-guided explanations and suggested follow-up questions. Biomarkers are measurable biological signals, such as blood lipids or glucose-related measures, that can help track health risk over time.
The model combines a recurring membership with repeated testing. That creates a longitudinal view of health rather than a one-time report and gives the software more context for helping users understand how results change over time.
02
1stBiome
Engineering probiotics that reduce low-grade gut inflammation for metabolic health.
- Country
Denmark- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why 1stBiome stands out
1stBiome entered BioInnovation Institute Venture Lab with €500,000 in financing and brings unusually strong repeat-founder experience. Morten Sommer previously co-founded Microlytic, acquired by Anatrace, while Ejner Bech Jensen previously co-founded Agrobiomics and led it through a €4 million seed round.
The product thesis also has early biological support. A 2026 preprint reported that the lead engineered probiotic reduced food intake and weight gain, increased energy expenditure and lowered inflammatory signaling in a mouse obesity model.
What 1stBiome is building
1stBiome engineers Saccharomyces boulardii, a probiotic yeast with established gastrointestinal use, to add new functions in the gut. The platform is intended to reduce low-grade inflammation and influence appetite and metabolic signaling through locally active biological mechanisms.
The startup plans oral nutritional products for metabolic health, weight management and healthy ageing, with commercialization through established consumer-health and nutrition brands rather than a standalone direct-to-consumer launch.
Developing targeted therapies for metabolic liver disease.
- Country
- Denmark
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Heureka Therapeutics stands out
Heureka Therapeutics combines a defined metabolic target with tissue-selective delivery. The startup joined BioInnovation Institute Venture Lab with €500,000 in financing, while co-founders Christoffer Clemmensen and Jonas Odgaard Petersen previously helped build Ousia Pharma.
Its lead liver-targeted program has preclinical evidence in an obesity-linked fatty-liver model, and the startup has filed composition-of-matter intellectual property around the conjugates. That gives Heureka a development package built around both target biology and delivery specificity.
What Heureka Therapeutics is building
Heureka Therapeutics is developing peptide-drug conjugates for metabolic dysfunction-associated steatotic liver disease, a form of fatty-liver disease linked to metabolic dysfunction. A targeting peptide directs an AMPK-activating payload into liver cells, concentrating the effect in the tissue where the disease is centered.
AMPK is a cellular energy-sensing pathway involved in how cells manage fuel. Heureka's approach is designed to activate it in hepatocytes, the main functional cells of the liver, while limiting exposure in other tissues.
04
GoEcoFit
Building an AI workplace health platform for personalized prevention and wellbeing.
- Country
Germany- Founded
- 2023
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why GoEcoFit stands out
GoEcoFit has moved from a consumer wellness proposition into a defined employer channel. In 2026, the startup signed a one-year contract with BioPark Regensburg covering its platform and two metabolomics analyses for participating employees.
An exclusive partnership with lifespin adds laboratory metabolomics, the measurement of small molecules produced by metabolism, to the platform. That gives GoEcoFit a way to combine lifestyle data with objective biological measurements in a workplace-prevention model.
What GoEcoFit is building
GoEcoFit combines health questionnaires, lifestyle tracking, coaching content and biomarker data in one preventive-health platform for employees. AI is used to organize inputs into personalized recommendations and priorities rather than present every data point with equal weight.
The platform can incorporate metabolomics results alongside daily behavior and wellbeing information. For employers, the product is packaged as a structured prevention program rather than a standalone consumer app.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
This group shows a category moving in two directions at once. Prevention products are becoming more data-rich and recurring, while therapeutics are becoming more tissue-specific. Between them sits a growing set of biological platforms that aim to influence metabolism before the patient reaches advanced disease.
For investors, the commercial model matters as much as the biological mechanism. Mito Health and GoEcoFit depend on repeated engagement and distribution, 1stBiome depends on partner-led consumer-health commercialization, and Heureka Therapeutics follows a drug-development path. The strongest opportunities are likely to be the ones where the intervention and the route to market are equally clear.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on metabolic-health products that act at materially different points from prevention and repeated measurement through biological intervention and therapeutic development.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.